FCGR1A and neoplasm: The addition of tumor antigen-specific monoclonal antibodies led to enhanced ADCC via the CD64/16A fusion protein and allowed for efficient tumor antigen targeting in ovarian cancer cell lines and in mice with ovarian cancer xenografts.